Company Overview and News

 
Orgenesis Reports 143% Increase in Revenue and 316% Increase in Gross Profit for the Third Quarter of Fiscal 2018

2018-10-15 globenewswire
GERMANTOWN, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and provided a business update for the fiscal third quarter ended August 31, 2018.
ORGS

 
ORGS / Orgenesis, Inc. FORM 10-Q (Quarterly Report)

2018-10-12 sec.gov
Orgenesis Inc.: Form 10-Q - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended August 31, 2018 or [ ] T
ORGS

 
Orgenesis to Provide Keynote Address and Poster Presentation at the 2018 International Conference on Diabetes and Endocrinology

2018-10-11 globenewswire
GERMANTOWN, Md., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Professor Sarah Ferber, Ph.D., Founder and Chief Scientific Officer of Orgenesis, will provide they keynote address at the International Conference on Diabetes and Endocrinology on October 15-16, 2018 at the Radisson Narita in Tokyo, Japan.
ORGS

 
オージェネシス、日本のヘカバイオとライセンス契約を締結したことを発表

2018-10-05 globenewswire
オージェネシスについて オージェネシス (Orgenesis) は、垂直統合型のバイオ医薬品会社であり、細胞療法開発およびサポートサービスにおけるノウハウとユニークな経験を有している。同社では、イスラエルの子会社であるオージェネシス・リミテッド (Orgenesis Ltd.) を経由して、ヒト肝臓細胞をグルコース応答性の完全な機能を備えたインスリン産生細胞 (IPC) にリプログラミングできる技術を開発中である。オージェネシスでは、糖尿病患者自身の組織をインスリン産生細胞に変換することで、膵島細胞移植に伴われるドナー不足、コスト面、および慢性免疫抑制療法の必要性という大きな問題を克服できると考えている。また、グローバルな委託開発・製造組織 (CDMO) である同社の子会社マスザーセル・グローバル (Masthercell Global) を通じて、最適化されたプロセス産業化能力を細胞療法を扱う組織に提供し、その療法の販売開始をスピードアップさせることができる。マスザーセルのチームは、技術選択からビジネスモデリング、GMP製造、プロセス開発、品質管理などを網羅し、持続可能で手頃な価格の療法を患者に提供するという目標を顧客が成就できるように全力を尽くしている。マスザーセルは、ヨーロッパの戦略的中心地であるベルギー、ワロン地域にある医療産業団地、バイオウィン (Biowin) にある、検証済みの柔軟性のある施設で運営している。この統合されたアプローチは、生活を改善できる重要な治療を市場に投入するという同社の経営理念をサポートしている。詳しくは、www.
ORGS

 
Orgenesis Announces License Agreement with HekaBio in Japan

2018-10-04 globenewswire
GERMANTOWN, Md., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that it has entered into a License Agreement with HekaBio K.K., pursuant to the Joint Venture Agreement the parties entered into on July 10, 2018. Under the License and Joint Venture Agreements, HekaBio and Orgenesis will collaborate in the clinical development and commercialization of regeneration and cell and gene therapeutic products in Japan.
ORGS

 
ORGS / Orgenesis, Inc. FORM DEF 14A

2018-09-21 sec.gov
Orgenesis Inc. - Form DEF 14A - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X]
ORGS

 
ORGS / Orgenesis, Inc. PRER14A

2018-09-07 sec.gov
Orgenesis Inc. - Schedule PRE14A - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X
ORGS

 
Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation

2018-08-23 globenewswire
GERMANTOWN, Md. and BEER-SHEVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, along with BGN Technologies and the National Institute for Biotechnology in the Negev (NIBN), both affiliates of Ben-Gurion University of the Negev (BGU), today announced a collaboration to develop and commercialize a novel alginate scaffold technology for cell transplantation, with an initial focus on autoimmune diseases.
ORGS

 
ORGS / Orgenesis, Inc. FORM PRE 14A

2018-08-09 sec.gov
Orgenesis Inc.: Form PRE 14A - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] F
ORGS

 
Orgenesis Announces Collaboration between Secant Group and Atvio Biotech, a Wholly Owned Subsidiary of Masthercell Global, to Develop and Commercialize Scaffold Technologies for Advanced Cell Therapies

2018-07-30 globenewswire
Secant Group and Atvio Biotech to advance project under $1.8 million grant from the Israel-U.S. Binational Industrial R&D Foundation
ORGS

 
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-07-20 sec.gov
Orgenesis Inc. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2018 ORGENESIS INC. (
ORGS

 
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-07-17 sec.gov
Orgenesis Inc.: Form 8K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2018 ORGENESIS INC. (Exact name of registrant as specified in
ORGS

 
ORGS / Orgenesis, Inc. FORM NT 10-Q

2018-07-17 sec.gov
Orgenesis Inc.: Form 12b-25 - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):
ORGS

 
Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018

2018-07-17 globenewswire
GERMANTOWN, Md., July 17, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and provided a business update for the fiscal second quarter ended May 31, 2018.
ORGS

 
ORGS / Orgenesis, Inc. FORM 10-Q (Quarterly Report)

2018-07-17 sec.gov
Orgenesis Inc.: Form 10-Q - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended May 31, 2018 or [ ] TRANSITION
ORGS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 68619K105